Leap Therapeutics completes enrollment of 188 patients in Phase 2 DeFianCe study of DKN-01 for CRC

CYPHERPUNK TECHNOLOGIES INC.

Enrolled 188 patients in randomized controlled Part B of DeFianCe study (NCT05480306).
Evaluates DKN-01 + bevacizumab + chemo as second-line therapy for advanced colorectal cancer.
Primary endpoint: progression-free survival overall and in left-sided CRC subpopulation.
Initial data from Part B expected in mid-2025; Part A showed encouraging response rates.
Study expanded from 130 to 188 patients, reflecting investigator and patient interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.